

# Pomalyst REMS®

## Education and Counseling Checklist for Pharmacies

### POMALYST Risk Evaluation and Mitigation Strategy (REMS) program education and prescribing safety

Authorization No.: \_\_\_\_\_ Confirmation No.: \_\_\_\_\_ Confirmation Date: \_\_\_\_\_  
Pharmacy Name: \_\_\_\_\_  
Pharmacy Address: \_\_\_\_\_  
Counselor Name: \_\_\_\_\_ Work Phone: \_\_\_\_\_ Ext.: \_\_\_\_\_  
Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
Risk Category: \_\_\_\_\_

#### Checklist for female patients of reproductive potential

- I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

#### I COUNSELED ADULTS AND CHILDREN ON:

- Potential embryo-fetal toxicity
- Not taking POMALYST® (pomalidomide) if pregnant or breastfeeding
- Using **at the same time** at least 1 highly effective method—tubal ligation, IUD, hormonal (birth control pills, hormonal patches, injections, vaginal rings, or implants), or partner’s vasectomy—and at least 1 additional effective method of birth control—male latex or synthetic condom, diaphragm, or cervical cap—**every time they have sex with a male**, or abstaining from sex with a male
- Unacceptable methods of birth control are progesterone-only “mini-pills,” IUD Progesterone T, female condoms, natural family planning (rhythm method) or breastfeeding, fertility awareness, withdrawal, and cervical shield (a cervical shield should not be confused with a cervical cap, which is an effective secondary form of contraception)
- Continuing to use **at the same time** at least 1 highly effective method and at least 1 additional effective method of birth control beginning at least 4 weeks before taking POMALYST, while taking POMALYST, during dose interruptions, and for at least 4 weeks after stopping POMALYST **every time they have sex with a male**, or abstaining from sex with a male
- Obtaining a pregnancy test—performed by their healthcare provider—weekly during the first 4 weeks of use. Thereafter, pregnancy testing should be repeated every 4 weeks during the rest of their treatment in females with regular menstrual cycles or no cycle at all. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks
- The need to stop taking POMALYST right away in the event of becoming pregnant, or if they think for any reason they may be pregnant, and to call their healthcare provider immediately
- Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke
- Not sharing POMALYST capsules with anyone—especially with females who can get pregnant
- Not donating blood while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST
- Not breaking, chewing, or opening POMALYST capsules
- Instructions on POMALYST dose and administration

Milligram (mg) Strength \_\_\_\_\_

Number of Capsules Dispensed \_\_\_\_\_

#### FEMALE CHILDREN (<18 YEARS OF AGE):

- Parent or legal guardian must have read the POMALYST REMS® education material and agreed to ensure compliance

#### Checklist for female patients not of reproductive potential (natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy)

- I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

#### I COUNSELED ADULTS AND CHILDREN ON:

- Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke
- Not sharing POMALYST capsules with anyone—especially with females who can get pregnant
- Not donating blood while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST
- Not breaking, chewing, or opening POMALYST capsules
- Instructions on POMALYST dose and administration

Milligram (mg) Strength \_\_\_\_\_

Number of Capsules Dispensed \_\_\_\_\_

#### FEMALE CHILDREN (<18 YEARS OF AGE):

- Parent or legal guardian must have read the POMALYST REMS® education material and agreed to ensure compliance
- Parent or legal guardian must inform the child’s healthcare provider when the child begins menses

## Checklist for male patients

- I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

### I COUNSELED ADULTS AND CHILDREN ON:

- Potential embryo-fetal toxicity and contraception (wearing a latex or synthetic condom **every time** when engaging in sexual intercourse with a female who can get pregnant, even if the patient has had a successful vasectomy)
- Female partners of males taking POMALYST® (pomalidomide) must call their healthcare provider right away if they get pregnant
- Possible side effects include deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke
- Not sharing POMALYST capsules with anyone—especially with females who can get pregnant
- Not donating blood or sperm while taking POMALYST (including dose interruptions) and for 4 weeks after stopping POMALYST
- Not breaking, chewing, or opening POMALYST capsules
- Instructions on POMALYST dose and administration

Milligram (mg) Strength \_\_\_\_\_

Number of Capsules Dispensed \_\_\_\_\_

### MALE CHILDREN (<18 YEARS OF AGE):

- Parent or legal guardian must have read the POMALYST REMS® education material and agreed to ensure compliance

**All boxes and spaces must be marked or filled in during counseling with the patient for every prescription.**

**Counselor Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

For more information about POMALYST and the POMALYST REMS® program, please visit [www.CelgeneRiskManagement.com](http://www.CelgeneRiskManagement.com), or call the Celgene Customer Care Center at **1-888-423-5436**.

Celgene Corporation  
86 Morris Ave  
Summit, NJ 07901

**POMALYST is only available under a restricted distribution program, POMALYST REMS®.**

**Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.**



**Pomalyst REMS®**

**Pomalyst**  
*(pomalidomide) capsules*

POMALYST® and POMALYST REMS® are registered trademarks of Celgene Corporation.

© 2017 Celgene Corporation

7/17

REMS-POM16895